Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Favorable Government Funding For Vaccine Development
4.2.2 Rising Prevalence of Diseases
4.2.3 Increase in R&D Expenditure by the Companies
4.3 Market Restraints
4.3.1 Huge Capital Expenditures
4.3.2 Stringent Regulatory Framework
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Products
5.1.1 Autoimmune Disease Vaccines
5.1.2 Neurological Disease Vaccines
5.1.3 Cancer Vaccines
5.1.4 Infectious Disease Vaccines
5.1.5 Other Products
5.2 Technology
5.2.1 Allogeneic Vaccine
5.2.2 Autologous Vaccine
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agenus Inc.
6.1.2 Argos Therapeutic Inc.
6.1.3 Celldex Therapeutic Inc.
6.1.4 Cytos Biotechnology AG
6.1.5 Dendreon Corp
6.1.6 GlaxoSmithKline
6.1.7 Merck & Co.
6.1.8 Novartis
6.1.9 Pfizer
6.1.10 Vaccinogen Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS